Rezo Therapeutics
Rezo Therapeutics maps disease networks to discover drug targets and candidate therapies in straightforward terms. It combines unbiased experimental technologies with machine-learning-driven AI in a proprietary network-biology platform to generate actionable targets and therapeutic hypotheses. The platform is disease-agnostic but currently prioritizes oncology discovery programs. Rezo partners with biopharmaceutical companies and research institutions to advance discovery programs. Leadership includes founders and executives with academic and industry drug-discovery track records.
Rezo Therapeutics
Rezo Therapeutics maps disease networks to discover drug targets and candidate therapies in straightforward terms. It combines unbiased experimental technologies with machine-learning-driven AI in a proprietary network-biology platform to generate actionable targets and therapeutic hypotheses. The platform is disease-agnostic but currently prioritizes oncology discovery programs. Rezo partners with biopharmaceutical companies and research institutions to advance discovery programs. Leadership includes founders and executives with academic and industry drug-discovery track records.
TL;DR
Founded: 2021
Headquarters: South San Francisco, California, United States
Focus: AI-driven disease-network mapping for target identification; initial priority oncology
Series A: $78M (announced Nov 17, 2022)
Notable investors: SR One; Andreessen Horowitz (a16z Bio + Health); Norwest; SV Angel; Liquid 2; Hawktail
Company Overview
Problem Domain
Therapeutic target identification and early drug discovery using disease-network mapping and AI
Founded
2021
Industry
Biotechnology
Funding Track Record
$78,000,000
Round included additional participants such as SV Angel, Liquid 2 Ventures, and Hawktail
Investor Signal
“Strategic biotech and venture investors including corporate and life-science–focused funds”